SAN DIEGO, May 21, 2012 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading scientific enterprise R&D software and services company, today announced a strategic content sourcing collaboration with the Intellectual Property & Science division of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals. Further expanding Accelrys' dynamic partner network, the agreement accelerates innovation, speeds time-to-market and improves the competitiveness of pharmaceutical and biotech organizations by delivering relevant, current and expertly curated life sciences content from Thomson Reuters' Cortellis® for Informatics via the scientifically aware Accelrys Enterprise Platform and related Accelrys software offerings including Pipeline Pilot, Symyx Notebook by Accelrys and Isentris.
To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/accelrys-announces-strategic-collaboration-with-thomson-reuters-152113635.html
The Accelrys Enterprise Platform incorporates industry-leading cheminformatics applications and tools that meet the end-to-end needs of scientists to access, manage, analyze, report and share scientific information in a unified environment that ensures consistency, accuracy and completeness of the chemistry and associated data being represented. This strong chemistry foundation establishes Accelrys as the premier chemistry provider for Thomson Reuters' publishing and web operations.
"We are pleased to be working with Accelrys and the Accelrys Enterprise Platform to integrate information from Thomson Reuters Cortellis," said Joseph Donahue, senior vice president at Thomson Reuters. "Accelrys is known for its strength in the scientific enterprise R&D software and services market, and this partnership will offer more options to our mutual customers to access, analyze and drive actionable decisions from key content."The Accelrys Enterprise Platform is the first scientifically aware, service-oriented architecture that enables the integration and deployment of broad scientific solutions across multiple domains in the lab-to-plant process. Cortellis for Informatics provides web services for investigational drugs, drug targets, ontologies, patents, clinical trials and analytics in biopharmaceutical R&D. "Enabling life scientists to access Thomson Reuters Cortellis content through a new Component Collection built on the Accelrys Enterprise Platform will accelerate innovation by providing actionable information to pharma and biotech organizations," said Dr. Matt Hahn, senior vice president and chief technology officer at Accelrys. "Scientists gain convenient access to expertly refined content and analysis tools through a single, user-friendly source delivered via the most widely used integration platform in the life sciences industry." The Accelrys Partner Program enables industry collaborators to combine their own products and services with Accelrys technologies on a single, scientifically aware platform, reducing costs, enhancing organizational efficiency, optimizing IT infrastructure and improving innovation lifecycle management in new scientific areas. Beta testers at top-30 pharmaceutical companies are currently assessing the new Thomson Reuters Component Collection on the Accelrys Enterprise Platform. When beta testing is complete, this new data sourcing solution from Accelrys and Thomson Reuters will be generally available to organizations wishing to derive full value from Thomson Reuters Cortellis content. For more information, contact your Thomson Reuters or Accelrys representative. You can also register for our jointly hosted webinar, " The New Thomson Reuters Cortellis Collection for Accelrys," to be held on Wednesday, May 23, 8:00 a.m. to 9:00 a.m. PDT. About Accelrys, Inc.Accelrys (NASDAQ:ACCL), a leading scientific enterprise R&D software and services company, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad, flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market. Accelrys solutions are used by more than 1,300 customers in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, Calif., Accelrys employs more than 200 full-time PhD scientists. For more information about Accelrys, visit www.accelrys.com. About Thomson ReutersThomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges. For more information, go to thomsonreuters.com. Related Links: Accelrys Website About Scientific Innovation Lifecycle Management SOURCE Accelrys, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV